
Leading Specialist
Biography
Professional Career and Clinical Experience
2006 to present
Medical Director of the Medias Klinikum Oncology Centre
Founded and leads the specialised medical centre in Burghausen. Under his leadership, the clinic has become a leading international centre for interventional oncology, treating patients with isolated organ perfusion and regional chemotherapy (RCT).
2002
President of the German Society for Regional Chemotherapy (SGKRCT)
Initiated the creation of a German professional medical society dedicated to standardising protocols for intra-arterial therapy. Served as President, coordinating clinical research across the EU.
1982
World’s first isolated liver perfusion via a vascular graft
Successfully performed the first isolated liver perfusion procedure using a specialised vascular graft, opening up the possibility of safely delivering high-dose local treatment to metastatic tumours.
1974 – 1981
Clinical Residency and Medical Training
Completed specialist medical training at Friedrich-Alexander University Erlangen-Nürnberg. Undertook extensive practical training in general and vascular surgery at clinics in Giessen and the United States.
Professor Karl Aigner received his basic medical education at Friedrich-Alexander University Erlangen-Nürnberg, where he also specialised in surgery. He has more than 40 years of clinical experience in surgical oncology. Over the course of his career, he has led major surgical departments in Germany while developing techniques for vascular isolation of organs. From the outset, Aigner has based his work on a multidisciplinary approach: in Burghausen, each patient’s treatment strategy is assessed by a surgeon, interventional radiologist and oncologist to determine the angiographic accessibility of the tumour.
Key Areas of Expertise
Regional Chemotherapy (RCT)
Local delivery of ultra-high doses of cytostatic drugs directly into the arteries supplying the tumour, bypassing the systemic circulation
Isolated Organ Perfusion
Surgical isolation of the affected organ, such as the liver or lung, from the systemic circulation to deliver high-dose local tumour treatment
Treatment of Inoperable Cancer
Reduction of advanced pancreatic and gastric tumours to potentially enable subsequent surgical treatment
Treatment of Peritoneal Carcinomatosis
Hypoxic abdominal perfusion (HAP) to control ascites associated with gastric and ovarian cancer
Organ-Sparing Surgery
Local control of breast and pelvic tumours without the need for radical amputations
Overcoming Chemoresistance
Targeting tumours that are resistant to standard lines of systemic intravenous chemotherapy
Professor Aigner’s Personal Approach
“Stage IV cancer is not the end; it is a reason to change the treatment strategy. If systemic chemotherapy no longer works or is damaging the patient’s body, we cannot afford to give up. My goal is to direct a high-dose treatment precisely at the target while protecting the patient. We are not simply fighting to prolong life, but to preserve a full and active quality of life, restoring hope where others have seen only statistics.”
patients annually
About Medias Klinikum Oncology Centre in Burghausen
Under the leadership of Professor Karl R. Aigner, the clinic in Bavaria is a leading international centre for interventional and regional oncology. The department specialises in advanced treatment of pancreatic, gastric and liver cancers, as well as peritoneal carcinomatosis, using advanced techniques for vascular isolation of tumour sites.
✓ More than 45 years of continuous clinical experience and a highly specialised focus give patients through kliniki.de access to unique organ-sparing medical technologies.
Scientific Recognition and Expertise
Main Research Focus
Regional Therapy and Isolated Organ Perfusion
Development, implementation and standardisation of intra-arterial infusion and isolated organ perfusion techniques. Author of fundamental medical monographs on interventional oncology. Professor Aigner has experimentally demonstrated the clinical effectiveness of local cytostatic drug delivery in overcoming tumour cell resistance.
| International Congress | Presentation Topic and Verified Data |
|---|---|
| European Society of Surgical Oncology (ESSO) | Analysis of survival and outcomes following upper abdominal perfusion. The principles of dosing and the effectiveness of the method are described in the publication: “Intra-arterial infusion chemotherapy versus mitomycin…”. |
| World Congress on Melanoma | Presentation on regional chemotherapy as a second-line treatment. Clinical outcomes for metastatic lesions and squamous cell carcinoma are presented in the study: “Regional Chemotherapy as a Valuable Second-Line…”. |
| Symposia of the German Society for Regional Chemotherapy (SGKRCT) | Presentations as a founding member of the society. The talks focus on overcoming platinum resistance in peritoneal disease, with detailed data published in the article: “Isolated Hypoxic Abdominal Perfusion (HAP)”. |
Services and price
- Serviceprice, €Additionally
- Online consultation 550 Oncology
